Personalized Healthcare for inflammatory diseases
Rheumatoid factor and/or anti-CCP status facilitate the prognosis for a better response to a modern therapeutic antibody and provide support for treatment decision-making.
Personalized Healthcare — rheumatoid arthritis (RA)
Rheumatoid arthritis (RA) is the most common and serious inflammatory joint disease and currently affects 800,000 people in Germany.1 RA is an autoimmune disease, i.e., the body is fighting itself. The continuous attack on the synovium by the body's own antibodies causes chronic inflammation in the form of swollen, painful joints that can result in stiffening and loss of mobility if left untreated.
Today we know that B-cells play a major role in the development and continuation of RA.
Figure: The therapeutic antibody (green)
binds in a targeted manner to the
CD20 molecule (red) on the surface
of B-cells (orange) thus removing
it from circulation.
With the help of an innovative antibody, the inflammation-causing B-cells can be removed from the blood in a targeted manner.
The antibody is the first and only approved biological agent with a targeted effect on B-cells in the treatment of RA. 2 In combination with a disease-modifying anti-rheumatic drug, this antibody helps to reduce inflammation and inhibit disease progress.
The diagnosis of RA is based on clinical symptoms and lab tests for specific inflammation markers. Roche provides all relevant diagnostic tests. The rheumatoid factor (RF) and the anti-cyclic citrullinated peptide (anti-CCP) are two typical biomarkers found in the majority of RA patients.
The rheumatoid factor and/or the anti-CCP status facilitate the prognosis for a better response to the antibody and can support physicians in making treatment decisions.
- Press release Hoffmann-La Roche Ltd., June 17, 2010
- Deutsche Rheuma-Liga Bundesverband e.V: Rheumatoid arthritis information sheet. 4th edition 2008